TCM
APVO icon

Tang Capital Management’s Aptevo Therapeutics APVO Stock Holding History

Tang Capital Management’s Portfolio APVO Stock Details APVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed -$27.2M – 30
2021
Q3 		$27.2M Hold
3
– – 5.64% 6
2021
Q2 		$39.5M Hold
3
– – 7.86% 6
2021
Q1 		$53.7M Hold
3
– – 15.11% 3
2020
Q4 		$64.5M Buy
+3
New +$48.7M 9.85% 3

Other funds holding APVO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tang Capital Management's APVO Position: Q4 2021 in Review

Tang Capital Management sold out of Aptevo Therapeutics (APVO) in Q4 2021, closing a stake of 3 shares — an estimated $27.2M sold.

Tang Capital Management first reported a position in APVO in Q4 2020 and held it in 4 quarters. The position peaked at $64.5M in Q4 2020. 0 funds tracked by Wall St. Rank hold APVO as of Q4 2021.

  • Tang Capital Management reported no remaining Aptevo Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Tang Capital Management sold 3 Aptevo Therapeutics shares in Q4 2021, an estimated $27.2M.
  • Tang Capital Management first reported a position in Aptevo Therapeutics in Q4 2020 and held it in 4 quarters.
  • Tang Capital Management's Aptevo Therapeutics position peaked at $64.5M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q4 2021.

Based on Tang Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.